Citi analyst Yigal Nochomovitz initiated coverage of Neurocrine (NBIX) with a Buy rating and $175 price target The firm believes the company’s pipeline success this year has been overshadowed by Ingrezza competitive concerns. Ingrezza is well positioned to at least maintain its current market share and the stock is attractive at current levels, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $168 from $163 at Morgan Stanley
- Positive Outlook for Neurocrine Biosciences Amidst Strong Prescription Growth and Strategic Positioning
- Neurocrine presents new data from Phase 3, open-label KINECT 4 study
- Neurocrine price target raised to $195 from $188 at UBS
- Neurocrine presents new data from KINECT-HD2 study of ingrezza